Choux 2003

1 Treatments

Studied treatment metformin 500 mg TID

Control treatment placebo

Concomittant treatments -

Women (%) -

Age (mean), years -

2 Patients

Patients PCO

Inclusion criteria -

Exclusion criteria -

Weight (kg) -

Body-mass index (kg/m2) -

Waist circumference (cm) -

obesity -

Family history of diabetes mellitus (%) -

Definitions of impaired glucose tolerance and type 2 diabetes -

3 Methods

Blinding -

Design -

Centers -

Geographical area -

Sizes 15/17

fasting plasma glucose (mmol/L) -
2-h plasma glucose (mmol/L) -

Dyslipidaemia -

2hPG (>9.4–11.0 mmol/L) -

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>hospitalization for heart failure</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>death</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV death</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV death, MI, stroke</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>diabetes</td>
<td>-/15</td>
<td>-/17</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>fatal and non fatal MI</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>normoglycemia</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>fatal and non fatal stroke</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cardiovasculaire events</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References